Login to Your Account

Eleven Biotherapeutics doses first patients in phase III of EBI-005

By Michael Fitzhugh
Staff Writer

Wednesday, August 12, 2015

Eleven Biotherapeutics Inc. dosed the first patients in a new phase III study testing lead candidate EBI-005 eye drops for moderate to severe allergic conjunctivitis, sending shares up 74.8 percent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription